Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

Tips for Balancing Medication Treatment & Risk in Elderly Patients

Thomas R. Collins  |  March 15, 2021

ACR CONVERGENCE 2020—With the inevitable decline in organ function that comes with age, and the likelihood that older patients (i.e., generally defined as older than 60 or 70, depending on the study) are on more than one medication due to multiple comorbidities, therapeutic drug treatment for older patients requires persistent vigilance and know-how, two experts…

Filed under:Conditions Tagged with:ACR Convergence 2020adverse drug reactionelderly

Micromotors Promising for Rheumatoid Arthritis Therapy

Marilynn Larkin  |  March 10, 2021

NEW YORK (Reuters Health)—Magnesium-based micromotors showed promise as a delivery system for hydrogen therapy to inflamed joints in an experimental model of rheumatoid arthritis, researchers say. Hydrogen gas has been shown to neutralize overproduction of reactive oxygen species (ROS), which can degrade cartilage and bone and activate inflammatory cytokines, according to Dr. Yingfeng Tu of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:micromotorsRheumatoid Arthritis (RA)

Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

Matthew Phelan  |  March 10, 2021

NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1 “Denosumab may be considered as an alternative first-line…

Filed under:Drug Updates Tagged with:alendronatebone lossbone mineral density (BMD)denosumabGlucocorticoids

Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

Michele B. Kaufman, PharmD, BCGP  |  March 5, 2021

In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.

Filed under:Biologics/DMARDsConditions Tagged with:CanadaCT-P13Drug SafetyFDAinfliximabRheumatoid Arthritis (RA)Tofacitinib

Wisconsin Rheumatology Association Targets Rural Workforce Shortages, Advocacy Needs

Linda Childers  |  February 26, 2021

Now in its 16th year, the Wisconsin Rheumatology Association engages and supports rheumatology professionals through advocacy sessions, annual meetings and continuing medical education-accredited events.

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Association of Rheumatology Professionals (ARP)Daniel MaloneState and local updatestate societyWisconsin Rheumatology Association

Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients

Lisa Rapaport  |  February 24, 2021

(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests. Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Anti-TNFanti-TNF agentpregnancypregnant womenRheumatoid Arthritis (RA)Women

The ACR Addresses Vaccine Challenges

David R. Karp, MD, PhD  |  February 18, 2021

An ACR COVID-19 Vaccine task force examined vaccine data and literature to evaluate COVID-19 vaccine safety, efficacy and interaction with medications for patients with rheumatic and musculoskeletal diseases, and to craft a living guidance document for members.

Filed under:American College of RheumatologyPresident's Perspective Tagged with:COVID-19Dr. David Karpvaccine

The ACR’s 2020 Advocacy Year in Review

Blair Solow, MD, & Zachary Wallace, MD, MSc  |  February 16, 2021

To say it has been an interesting (the science and the memes), tumultuous (the politics) and heartbreaking (the pandemic and social injustice) year is an understatement. There have been moments of grace and inspiration that we hope have kept everyone going.  As we look to 2021, we take lessons from our experiences in 2020. Washington,…

Filed under:From the CollegeLegislation & Advocacy Tagged with:Centers for Medicare & Medicaid Services (CMS)RheumPACstep therapytelehealthU.S. Congress

The Unapproved-Drugs Initiative Is Coming to an End

Jason Melehani, MD, PhD  |  February 16, 2021

On Friday, Nov. 20, 2020, the U.S. Department of Health and Human Services (HHS) published a Notice through the Federal Register announcing the withdrawal of guidance documents that established the Unapproved Drugs Initiative. This Notice brings to an end a 14-year-old program that has been blamed for significantly contributing to the rising cost of some…

Filed under:Drug Updates Tagged with:Unapproved Drugs Initiative

The ARP Revises Its Fundamentals of Rheumatology Course

Hiral Master, PT, PhD, MPH, Teresa J. Brady, PhD, Aileen Ledingham, PT, MS, PhD, & Carole Dodge, OT, CHT, on behalf of the ARP eLearning Subcommittee  |  February 16, 2021

The ARP’s revised Fundamentals of Rheumatology Course (FRC) will soon be released on the ACR website. The course was revamped by interdisciplinary rheuma­tology professionals emphasizing an inter-professional approach to patient care. It is intended to reach a broad audience, including nurses, occupational therapists, pharmacists, physical therapists, psychologists and social workers to name a few. However,…

Filed under:Education & Training Tagged with:Association of Rheumatology Professionals (ARP)

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 125
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences